Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html


Study Counts

Type Study_count
Total_Studies 267
interventional 236
Observational 28
Registry 3

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Drug 113
Biological 25
Biological|Drug 17
Drug|Other 12
Drug|Procedure 10
Other 8
Drug|placebo 5
Drug|Procedure|Radiation 5
Procedure 5
Drug|Other|placebo 3
Radiation 3
Behavioral 2
Biological|Other 2
Combination Product 2
Device|Drug 2
Other|Procedure 2
Behavioral|Dietary Supplement 1
Behavioral|Other 1
Biological|Device|Drug 1
Biological|Drug|Other 1
Biological|Drug|Other|placebo 1
Biological|Drug|Other|Procedure 1
Biological|Drug|Procedure|Radiation 1
Biological|Genetic|Other 1
Biological|Other|Procedure 1
Biological|Other|Radiation 1
Biological|Procedure 1
Device 1
Device|Drug|Procedure 1
Device|Other 1
Diagnostic Test 1
Dietary Supplement|Drug|Genetic|Other 1
Drug|Genetic 1
Drug|Radiation 1
Genetic 1
Procedure|Radiation 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
United States 127
United Kingdom 13
Canada 9
Italy 8
Netherlands 7
France 6
Japan 6
China 5
Switzerland 4
NA 3
Australia 2
Denmark 2
United States|Canada 2
United States|Spain 2
Australia|Denmark|Norway|Spain|Sweden 1
Australia|New Zealand|Poland|Russian Federation|Thailand 1
Australia|United Kingdom 1
Belgium 1
Belgium|Canada|Egypt|France|Germany|Italy|Netherlands|Peru|Poland|Switzerland|United Kingdom 1
Belgium|France 1
Belgium|France|Germany|Italy|Netherlands|Poland|Spain 1
Belgium|France|Italy|Netherlands|United Kingdom 1
Belgium|France|Netherlands 1
Belgium|Ireland|Netherlands|United Kingdom 1
Belgium|Italy|Netherlands|United Kingdom 1
Belgium|Italy|United Kingdom 1
Belgium|Netherlands 1
Canada|France|Italy 1
China|United States|Australia|Belgium|Brazil|Chile|Colombia|France|Germany|Greece|Italy|Japan|Mexico|Netherlands|Poland|Romania|Russian Federation|South Africa|Switzerland|Turkey|United Kingdom 1
Denmark|Germany|Spain 1
France|Italy|Belgium|Spain|Switzerland|United Kingdom 1
France|Spain 1
Germany 1
Germany|Italy|Russian Federation 1
Germany|Switzerland 1
Israel 1
Italy|Netherlands 1
Italy|United States|Netherlands|Spain 1
Slovenia 1
Spain|Switzerland|United Kingdom 1
Spain|United States|Australia|Belgium|Canada|Denmark|France|Germany|Hungary|Israel|Italy|Korea, Republic of|Netherlands|Poland|Romania|Russian Federation|South Africa|Sweden|United Kingdom 1
Sweden 1
Switzerland|Italy 1
United States|Australia|Belgium|Canada|Finland|France|Italy|Korea, Republic of|Netherlands|Poland|Russian Federation|Spain|Turkey|United Kingdom 1
United States|Australia|Canada|France|Germany|Poland|Russian Federation|United Kingdom 1
United States|Australia|France|Poland|United Kingdom 1
United States|Australia|Italy|Taiwan|United Kingdom 1
United States|Belgium|Canada|Egypt|France|Ireland|Italy|Netherlands|Poland|Spain|Sweden|United Kingdom 1
United States|Canada|Germany|Netherlands|Spain 1
United States|Finland|Netherlands|Sweden|United Kingdom 1
United States|France|Spain 1
United States|France|United Kingdom 1
United States|Italy 1
United States|Italy|Puerto Rico 1

Sites per Study

Site_count Study_Count
1 117
2 13
3 16
4 7
5 11
6 5
7 9
8 7
9 2
10 2
11 2
12 3
13 4
14 2
15 2
16 1
17 1
18 1
19 1
20 2
22 1
23 1
24 2
25 2
26 1
28 2
35 1
37 1
43 1
45 1
49 1
50 1
58 1
75 1
80 1
81 1
84 1
104 1
109 1
115 1
129 1
145 1
179 1
232 1
938 1

Phase

Phase Study_Count
Phase 2 101
Phase 1 68
Phase 1/Phase 2 29
N/A 15
Phase 3 14
Phase 2/Phase 3 4
Early Phase 1 3
Phase 4 2

Number of Arms

Number_of_Arms Count_of_Studies
1 114
2 62
3 10
4 6
5 2
6 4
7 1
9 1
11 1
15 1
NA 34

Enrollment Metrics by Phase

Measure Early.Phase.1 N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.2.Phase.3 Phase.3 Phase.4
Min. 1.0 9.0000 6.00000 10.00000 2.00 126.0 44 10
1st Qu. 2.5 19.0000 18.00000 27.00000 30.00 204.0 240 31
Median 4.0 38.0000 28.00000 55.00000 49.00 308.0 320 52
Mean 16.0 126.6667 58.25397 70.75862 76.06 297.5 365 52
3rd Qu. 23.5 279.5000 57.00000 71.00000 78.75 401.5 405 73
Max. 43.0 350.0000 500.00000 424.00000 818.00 448.0 840 94

Trial Group Type

group_type Group_Count
Experimental 307
Active Comparator 34
NA 34
Placebo Comparator 12
Other 10
No Intervention 5

Intervention Model

intervention_model Study_Count
Single Group Assignment 136
Parallel Assignment 63
NA 18
Sequential Assignment 17
Crossover Assignment 1
Factorial Assignment 1

Primary Purpose

primary_purpose Study_Count
Treatment 216
Supportive Care 8
Other 4
Diagnostic 3
Screening 2
Basic Science 1
Prevention 1
NA 1

Observational Studies

Studies by Country

Country Study_Count
United States 16
NA 3
Canada 2
Egypt 2
Belgium 1
France 1
Italy 1
Turkey 1
United Kingdom 1

Sites per Study

Site_count Study_Count
1 25
2 1
6 1
187 1

Enrollment Metrics

Measure Observational
Min 19.0000
1st Qu 68.7500
Median 198.0000
Mean 353.0714
3rd Qu 423.5000
Max 1452.0000

Observation Model

observational_model Study_Count
Cohort 15
Case-Only 8
Case-Control 2
Case Control 2
Case-Crossover 1

Time Perspective

time_perspective Study_Count
Prospective 21
Retrospective 5
Cross-Sectional 2

Registries

Studies by Country

Country Study_Count
Argentina|Australia|Austria|Belgium|Denmark|France|Germany|Italy|Poland|Russian Federation|Singapore|Spain|Switzerland 1
Norway 1
United States 1

Sites per Study

Site_count Study_Count
1 1
16 1
75 1

Enrollment Metrics

Measure Registries
Min 200.0
1st Qu 600.0
Median 1000.0
Mean 333733.0
3rd Qu 500499.5
Max 999999.0

Registry Model

observational_model Study_Count
Cohort 3

Time Perspective

time_perspective Study_Count
Prospective 3

Follow-up

target_duration Study_Count
1 Year 1
5 Years 1
80 Years 1

Overview of Studies

Interventional Trials

#If less then 500 trials

nct_id brief_title link overall_status source primary_completion_date
NCT04430842 Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S https://ClinicalTrials.gov/show/NCT04430842 Recruiting Quadriga Biosciences, Inc. 2021-09-30
NCT04042480 A Study of SGN-CD228A in Advanced Solid Tumors https://ClinicalTrials.gov/show/NCT04042480 Recruiting Seattle Genetics, Inc. 2023-01-31
NCT03393858 Combination of Immunotherapy and Hyperthermia in Advanced Malignant Mesothelioma https://ClinicalTrials.gov/show/NCT03393858 Recruiting Capital Medical University 2020-06-30
NCT03319537 Pevonedistat Alone and in Combination With Chemotherapy in Patients With Mesothelioma https://ClinicalTrials.gov/show/NCT03319537 Recruiting Memorial Sloan Kettering Cancer Center 2020-10-31
NCT03269227 Accelerated Hypofractionated Radiotherapy in the Treatment of Malignant Pleural Mesothelioma https://ClinicalTrials.gov/show/NCT03269227 Recruiting Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori 2020-07-31
NCT03228537 Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma https://ClinicalTrials.gov/show/NCT03228537 Active, not recruiting National Cancer Institute (NCI) 2021-06-01
NCT03213301 Lurbinectedin Monotherapy in Patients With Progressive Malignant Pleural Mesothelioma. https://ClinicalTrials.gov/show/NCT03213301 Active, not recruiting Swiss Group for Clinical Cancer Research 2019-04-08
NCT03212404 Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers https://ClinicalTrials.gov/show/NCT03212404 Recruiting Checkpoint Therapeutics, Inc. 2021-07-31
NCT03207347 A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001) https://ClinicalTrials.gov/show/NCT03207347 Recruiting University of Florida 2021-12-31
NCT03177668 Clinical Study of YS110 in Patients With Malignant Pleural Mesothelioma https://ClinicalTrials.gov/show/NCT03177668 Active, not recruiting Kissei Pharmaceutical Co., Ltd. 2020-12-31
NCT03126630 Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma https://ClinicalTrials.gov/show/NCT03126630 Recruiting National Cancer Institute (NCI) 2022-02-02
NCT03074513 Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors https://ClinicalTrials.gov/show/NCT03074513 Recruiting M.D. Anderson Cancer Center 2021-03-31
NCT03068117 Malignant Mesothelioma - Can we Improve Quality of Life https://ClinicalTrials.gov/show/NCT03068117 Completed Portsmouth Hospitals NHS Trust 2017-01-31
NCT03063450 CheckpOiNt Blockade For Inhibition of Relapsed Mesothelioma https://ClinicalTrials.gov/show/NCT03063450 Active, not recruiting University of Southampton 2021-07-31
NCT03054298 CAR T Cells in Mesothelin Expressing Cancers https://ClinicalTrials.gov/show/NCT03054298 Recruiting University of Pennsylvania 2021-03-31
NCT03048474 Ipilimumab and Nivolumab in the Treatment of Malignant Pleural Mesothelioma https://ClinicalTrials.gov/show/NCT03048474 Active, not recruiting The Netherlands Cancer Institute 2017-12-31
NCT03023319 Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors https://ClinicalTrials.gov/show/NCT03023319 Recruiting Augusta University 2020-11-30
NCT03007030 Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery https://ClinicalTrials.gov/show/NCT03007030 Recruiting M.D. Anderson Cancer Center 2022-04-30
NCT02991482 PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma https://ClinicalTrials.gov/show/NCT02991482 Active, not recruiting European Thoracic Oncology Platform 2020-12-31
NCT02959463 Phase I Trial of Adjuvant Pembrolizumab After Radiation Therapy for Lung-Intact Malignant Pleural Mesothelioma https://ClinicalTrials.gov/show/NCT02959463 Recruiting M.D. Anderson Cancer Center 2020-05-31
NCT02899299 Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients https://ClinicalTrials.gov/show/NCT02899299 Active, not recruiting Bristol-Myers Squibb 2021-04-15
NCT02899195 Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma https://ClinicalTrials.gov/show/NCT02899195 Active, not recruiting PrECOG, LLC. 2020-02-16
NCT02879669 A Randomised Phase II Open-label Study With a Phase Ib Safety lead-in Cohort of ONCOS-102, an Immune-priming GM-CSF Coding Oncolytic Adenovirus, and Pemetrexed/Cisplatin in Patients With Unresectable Malignant Pleural Mesothelioma https://ClinicalTrials.gov/show/NCT02879669 Active, not recruiting Targovax ASA 2020-06-30
NCT02875548 Tazemetostat Rollover Study (TRuST): An Open-Label Rollover Study https://ClinicalTrials.gov/show/NCT02875548 Recruiting Epizyme, Inc. 2023-12-31
NCT02863055 Nintedanib as Switch Maintenance Treatment of Pleural Malignant Mesothelioma https://ClinicalTrials.gov/show/NCT02863055 Recruiting European Organisation for Research and Treatment of Cancer - EORTC 2020-12-31
NCT02860286 Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma https://ClinicalTrials.gov/show/NCT02860286 Completed Epizyme, Inc. 2018-06-30
NCT02859415 Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases https://ClinicalTrials.gov/show/NCT02859415 Recruiting National Institutes of Health Clinical Center (CC) 2028-08-03
NCT02838745 Study of Cytoreductive Surgery and Hyperthermic Intraoperative Chemotherapy With Pemetrexed and Cisplatin for Malignant Pleural Mesotheliomas https://ClinicalTrials.gov/show/NCT02838745 Recruiting Baylor College of Medicine 2022-07-31
NCT02798536 Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma https://ClinicalTrials.gov/show/NCT02798536 Active, not recruiting National Institutes of Health Clinical Center (CC) 2017-07-20
NCT02758587 Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1) https://ClinicalTrials.gov/show/NCT02758587 Recruiting NHS Greater Glasgow and Clyde 2019-05-31
NCT02755675 uPAR-PET for Prognostication in Patients With Non-small Cell Lung Cancer, Malignant Pleural Mesothelioma and Large Cell Neuroendocrine Carcinoma of the Lung https://ClinicalTrials.gov/show/NCT02755675 Recruiting Rigshospitalet, Denmark 2023-04-30
NCT02716272 Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) Patients https://ClinicalTrials.gov/show/NCT02716272 Active, not recruiting Intergroupe Francophone de Cancerologie Thoracique 2018-02-28
NCT02709512 Ph 2/3 Study in Subjects With MPM to Assess ADI-PEG 20 With Pemetrexed and Cisplatin https://ClinicalTrials.gov/show/NCT02709512 Recruiting Polaris Group 2020-10-31
NCT02707666 A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma https://ClinicalTrials.gov/show/NCT02707666 Recruiting University of Chicago 2022-12-20
NCT02662504 Intrapleural Photodynamic Therapy in a Multimodal Treatment for Patients With Malignant Pleural Mesothelioma https://ClinicalTrials.gov/show/NCT02662504 Completed University Hospital, Lille 2018-03-12
NCT02649829 Autologous Dendritic Cell Vaccination in Mesothelioma https://ClinicalTrials.gov/show/NCT02649829 Recruiting University Hospital, Antwerp 2020-10-31
NCT02639091 Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors https://ClinicalTrials.gov/show/NCT02639091 Completed Bayer 2018-05-23
NCT02637531 A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 https://ClinicalTrials.gov/show/NCT02637531 Active, not recruiting Infinity Pharmaceuticals, Inc. 2020-12-31
NCT02611037 Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma https://ClinicalTrials.gov/show/NCT02611037 Recruiting H. Lee Moffitt Cancer Center and Research Institute 2020-12-31
NCT02611024 Pharmacokinetic Study of PM01183 in Combination With Irinotecan in Patients With Selected Solid Tumors https://ClinicalTrials.gov/show/NCT02611024 Recruiting PharmaMar 2020-11-30
NCT02610140 Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM) https://ClinicalTrials.gov/show/NCT02610140 Completed Bayer 2017-05-31
NCT02599194 18F-FSPG PET/CT for Cancer Patients on Therapy https://ClinicalTrials.gov/show/NCT02599194 Completed Stanford University 2016-12-14
NCT02592551 MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma https://ClinicalTrials.gov/show/NCT02592551 Active, not recruiting Baylor College of Medicine 2020-09-01
NCT02585362 Whey Protein Supplement in Combination With Physical Exercise and Nutrition Program https://ClinicalTrials.gov/show/NCT02585362 Completed Kantonsspital Winterthur KSW 2018-10-31
NCT04153565 A Study of Pembrolizumab in Combination With Cisplatin and Pemetrexed in Advanced Malignant Pleural Mesothelioma (MPM) (MK-3475-A17) https://ClinicalTrials.gov/show/NCT04153565 Active, not recruiting Merck Sharp & Dohme Corp. 2021-06-30
NCT02568449 Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent https://ClinicalTrials.gov/show/NCT02568449 Active, not recruiting Barbara Ann Karmanos Cancer Institute 2019-06-01
NCT04034238 Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors https://ClinicalTrials.gov/show/NCT04034238 Recruiting National Institutes of Health Clinical Center (CC) 2022-12-01
NCT03399552 Stereotactic Body Radiation Therapy and Avelumab Immunotherapy for Treatment of Malignant Mesothelioma https://ClinicalTrials.gov/show/NCT03399552 Active, not recruiting Memorial Sloan Kettering Cancer Center 2021-12-31
NCT02535312 Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin https://ClinicalTrials.gov/show/NCT02535312 Active, not recruiting National Cancer Institute (NCI) 2020-12-31
NCT02497508 Nivolumab in Patients With Recurrent Malignant Mesothelioma https://ClinicalTrials.gov/show/NCT02497508 Completed The Netherlands Cancer Institute 2017-07-31
NCT02464904 Intrapleural Cryotherapy for Malignant Pleural Mesothelioma https://ClinicalTrials.gov/show/NCT02464904 Recruiting Mayo Clinic 2020-12-31
NCT02436733 Pleurectomy/ Decortication (P/D) Preceded or Followed by Chemotherapy in Patients With Early Stage MPM https://ClinicalTrials.gov/show/NCT02436733 Recruiting European Organisation for Research and Treatment of Cancer - EORTC 2019-09-30
NCT02414945 TILs & Low-Dose IL-2 Therapy Following Cyclophosphamide and Fludarabine in Pleural Mesothelioma Patients https://ClinicalTrials.gov/show/NCT02414945 Recruiting University Health Network, Toronto 2025-06-30
NCT02414269 Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin https://ClinicalTrials.gov/show/NCT02414269 Recruiting Memorial Sloan Kettering Cancer Center 2021-04-30
NCT02397928 Safety and Efficacy of TTFields (150 kHz) Concomitant With Pemetrexed and Cisplatin or Carboplatin in Malignant Pleural Mesothelioma (STELLAR) https://ClinicalTrials.gov/show/NCT02397928 Completed NovoCure Ltd. 2018-04-30
NCT02385812 Screening of Alberta Asbestos Exposed Workers for Lung Cancer and Mesothelioma https://ClinicalTrials.gov/show/NCT02385812 Recruiting University of Calgary 2022-12-31
NCT02369198 MesomiR 1: A Phase I Study of TargomiRs as 2nd or 3rd Line Treatment for Patients With Recurrent MPM and NSCLC https://ClinicalTrials.gov/show/NCT02369198 Completed Asbestos Diseases Research Foundation 2017-01-04
NCT02349958 Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy https://ClinicalTrials.gov/show/NCT02349958 Recruiting Bay Area Gynecology Oncology 2022-01-31
NCT02349412 Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers https://ClinicalTrials.gov/show/NCT02349412 Completed Alliance for Clinical Trials in Oncology 2017-07-03
NCT02347917 A Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma https://ClinicalTrials.gov/show/NCT02347917 Completed Sumitomo Dainippon Pharma Co., Ltd. 2018-05-31
NCT02293005 Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma https://ClinicalTrials.gov/show/NCT02293005 Active, not recruiting M.D. Anderson Cancer Center 2021-05-31
NCT02194231 ATREUS - Phase II Study on the Activity of Trabectedin in Patients With Malignant Pleural Mesothelioma (MPM) https://ClinicalTrials.gov/show/NCT02194231 Completed Mario Negri Institute for Pharmacological Research 2019-12-12
NCT02159716 CART-meso in Mesothelin Expressing Cancers https://ClinicalTrials.gov/show/NCT02159716 Completed University of Pennsylvania 2015-11-30
NCT02151448 αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies https://ClinicalTrials.gov/show/NCT02151448 Completed University of Pittsburgh 2019-02-18
NCT02141347 Ph1 to Assess Safety, Tolerability of Tremelimumab/ Tremelimumab+MEDI4736 in Japanese Solid Malignancies/ Mesothelioma https://ClinicalTrials.gov/show/NCT02141347 Completed AstraZeneca 2017-01-27
NCT02139904 Vinorelbine in Mesothelioma https://ClinicalTrials.gov/show/NCT02139904 Active, not recruiting Wales Cancer Trials Unit 2019-10-31
NCT02078700 Feasibility of an Early Palliative Care Intervention for Metastatic Cancer Patients. A Phase 2 Study. https://ClinicalTrials.gov/show/NCT02078700 Completed Arcispedale Santa Maria Nuova-IRCCS 2014-04-30
NCT02071862 Study of the Glutaminase Inhibitor CB-839 in Solid Tumors https://ClinicalTrials.gov/show/NCT02071862 Completed Calithera Biosciences, Inc 2019-03-31
NCT02040272 Mesothelioma and Radical Surgery 2 https://ClinicalTrials.gov/show/NCT02040272 Recruiting Royal Brompton & Harefield NHS Foundation Trust 2020-09-30
NCT02040142 Single Arm Study Treating Patients of Peritoneal Surface Malignancy (Colorectal, Appendical, Pseudomyxoma, Gastric) With Cytoreductive Surgery and Hyperthermic Intraperitoneal Mitomycin-C https://ClinicalTrials.gov/show/NCT02040142 Recruiting Albert Einstein College of Medicine 2021-11-30
NCT03762018 BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma https://ClinicalTrials.gov/show/NCT03762018 Recruiting European Thoracic Oncology Platform 2024-10-31
NCT02408016 Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma https://ClinicalTrials.gov/show/NCT02408016 Active, not recruiting Fred Hutchinson Cancer Research Center 2020-06-30
NCT01890980 Phase II Study of Adjuvant WT-1 Analog Peptide Vaccine in MPM Patients After MSK10-134 https://ClinicalTrials.gov/show/NCT01890980 Active, not recruiting M.D. Anderson Cancer Center 2020-04-30
NCT01843374 Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma https://ClinicalTrials.gov/show/NCT01843374 Active, not recruiting MedImmune LLC 2016-01-24
NCT02784171 Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma https://ClinicalTrials.gov/show/NCT02784171 Recruiting Canadian Cancer Trials Group 2022-07-31
NCT01722149 Re-directed T Cells for the Treatment (FAP)-Positive Malignant Pleural Mesothelioma https://ClinicalTrials.gov/show/NCT01722149 Completed University of Zurich 2019-03-22
NCT01721018 Intrapleural Administration of HSV1716 to Treat Patients With Malignant Pleural Mesothelioma. https://ClinicalTrials.gov/show/NCT01721018 Completed Virttu Biologics Limited 2016-11-14
NCT01675765 Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma https://ClinicalTrials.gov/show/NCT01675765 Completed Aduro Biotech, Inc. 2018-09-05
NCT01644994 Intracavitary Cisplatin-Fibrin Localized Chemotherapy After P/D or EPP for Malignant Pleural Mesothelioma https://ClinicalTrials.gov/show/NCT01644994 Active, not recruiting University of Zurich 2019-12-31
NCT01592383 Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal Mesothelioma https://ClinicalTrials.gov/show/NCT01592383 Completed University of Chicago 2017-02-28
NCT01590160 Ganetespib With Platinum, in Patients With Malignant Pleural Mesothelioma https://ClinicalTrials.gov/show/NCT01590160 Completed University College, London 2019-11-05
NCT01521325 A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers https://ClinicalTrials.gov/show/NCT01521325 Completed Morphotek 2013-03-31
NCT04300244 Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma https://ClinicalTrials.gov/show/NCT04300244 Recruiting Oslo University Hospital 2024-03-15
NCT01503177 Intrapleural Measles Virus Therapy in Patients With Malignant Pleural Mesothelioma https://ClinicalTrials.gov/show/NCT01503177 Active, not recruiting Mayo Clinic 2020-12-31
NCT01486368 A Phase II Study of PF-03446962 in Patients With Advanced Malignant Pleural Mesothelioma https://ClinicalTrials.gov/show/NCT01486368 Completed Canadian Cancer Trials Group 2014-04-27
NCT01401907 Early Palliative Care in Advanced Lung and Gastrointestinal Malignancies https://ClinicalTrials.gov/show/NCT01401907 Active, not recruiting Massachusetts General Hospital 2016-04-30
NCT01362790 SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma https://ClinicalTrials.gov/show/NCT01362790 Completed National Institutes of Health Clinical Center (CC) 2016-08-03
NCT01358084 Phase II Study of NGR-hTNF Versus Placebo as Maintenance Treatment in Patients With Advanced MPM https://ClinicalTrials.gov/show/NCT01358084 Completed MolMed S.p.A. 2018-12-05
NCT01355965 Autologous Redirected RNA Meso-CIR T Cells https://ClinicalTrials.gov/show/NCT01355965 Completed University of Pennsylvania 2015-07-31
NCT04375267 177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours https://ClinicalTrials.gov/show/NCT04375267 Recruiting Vastra Gotaland Region 2022-06-30
NCT04316689 First-in-human Study of S-588210 (S-488210+S-488211) https://ClinicalTrials.gov/show/NCT04316689 Recruiting Shionogi Inc. 2020-10-31
NCT04290325 HMPL-453 in Advanced Malignant Mesothelioma https://ClinicalTrials.gov/show/NCT04290325 Recruiting Hutchison Medipharma Limited 2022-11-30
NCT04234113 Study of SO-C101 and SO-C101in Combination With Pembro in Adult Patients With Advanced/Metastatic Solid Tumors https://ClinicalTrials.gov/show/NCT04234113 Recruiting Sotio a.s. 2022-03-31
NCT04213794 Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for the Treatment of Resectable, Refractory, or Recurrent Abdominal or Pelvic Tumors in Pediatric Patients, T.O.A.S.T. I.T. Study https://ClinicalTrials.gov/show/NCT04213794 Recruiting Mayo Clinic 2025-01-30
NCT04177953 Nivolumab With Chemotherapy in Pleural Mesothelioma After Surgery https://ClinicalTrials.gov/show/NCT04177953 Recruiting Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest 2023-07-31
NCT04173338 Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma https://ClinicalTrials.gov/show/NCT04173338 Recruiting Augusta University 2020-11-30
NCT04162015 A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma https://ClinicalTrials.gov/show/NCT04162015 Recruiting Memorial Sloan Kettering Cancer Center 2022-11-30
NCT04115111 Diadem to Investigate the Activity and Safety of Durvalumab https://ClinicalTrials.gov/show/NCT04115111 Active, not recruiting Mario Negri Institute for Pharmacological Research 2019-12-31
NCT04088786 Phase I Trial HIPEC With Nal-irinotecan https://ClinicalTrials.gov/show/NCT04088786 Recruiting Stony Brook University 2020-08-31
NCT04056026 A Single Dose FMT Infusion as an Adjunct to Keytruda for Metastatic Mesothelioma https://ClinicalTrials.gov/show/NCT04056026 Completed ProgenaBiome 2018-12-18
NCT04040231 Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma https://ClinicalTrials.gov/show/NCT04040231 Recruiting Memorial Sloan Kettering Cancer Center 2020-07-31
NCT04028570 A Feasibility Study Evaluating Surgery for Mesothelioma After Radiation Therapy Using Extensive Pleural Resection https://ClinicalTrials.gov/show/NCT04028570 Recruiting University Health Network, Toronto 2024-04-30
NCT04013334 MTG201 Plus Nivolumab in Patients With Relapsed Pleural Mesothelioma https://ClinicalTrials.gov/show/NCT04013334 Recruiting Momotaro-Gene Inc. 2020-09-20
NCT03983954 Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors https://ClinicalTrials.gov/show/NCT03983954 Recruiting NeoTX Therapeutics Ltd. 2021-11-01
NCT03935893 Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers https://ClinicalTrials.gov/show/NCT03935893 Recruiting University of Pittsburgh 2029-06-01
NCT03918252 Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma https://ClinicalTrials.gov/show/NCT03918252 Recruiting Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 2025-06-30
NCT03917043 APG-2449 in Patients With Advanced Solid Tumors https://ClinicalTrials.gov/show/NCT03917043 Recruiting Ascentage Pharma Group Inc. 2021-05-31
NCT03907852 Phase 1/2 Trial of TC-210 T Cells in Patients With Advanced Mesothelin-Expressing Cancer https://ClinicalTrials.gov/show/NCT03907852 Recruiting TCR2 Therapeutics 2021-06-30
NCT03867578 Magnetic Resonance Imaging for Detection of Peritoneal Mesothelioma https://ClinicalTrials.gov/show/NCT03867578 Recruiting University of Chicago 2022-01-22
NCT03852823 Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours https://ClinicalTrials.gov/show/NCT03852823 Recruiting CSPC ZhongQi Pharmaceutical Technology Co., Ltd. 2022-09-30
NCT03715933 Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas https://ClinicalTrials.gov/show/NCT03715933 Recruiting Inhibrx, Inc. 2020-07-31
NCT03710876 Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma https://ClinicalTrials.gov/show/NCT03710876 Recruiting Trizell Ltd 2023-11-30
NCT03684486 Rehabilitation by Effort for Patients With Advanced Bronchial Cancer https://ClinicalTrials.gov/show/NCT03684486 Recruiting University Hospital, Toulouse 2020-02-01
NCT03683680 Prospectively Collected Pleural Biopsies for Validation of Malignant Pleural Mesothelioma Prognostic Biomarkers https://ClinicalTrials.gov/show/NCT03683680 Recruiting Dana-Farber Cancer Institute 2022-01-01
NCT03656549 Dose Individualization of Pemetrexed - IMPROVE-I https://ClinicalTrials.gov/show/NCT03656549 Recruiting Radboud University 2021-10-01
NCT03655834 Dose Individualization of Pemetrexed - IMPROVE-III https://ClinicalTrials.gov/show/NCT03655834 Recruiting Radboud University 2021-09-01
NCT03655821 Dose Individualization of Pemetrexed - IMPROVE-II https://ClinicalTrials.gov/show/NCT03655821 Recruiting Radboud University 2021-09-01
NCT03654833 Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma https://ClinicalTrials.gov/show/NCT03654833 Recruiting University of Leicester 2021-07-30
NCT03644550 Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant Mesothelioma https://ClinicalTrials.gov/show/NCT03644550 Recruiting National Institutes of Health Clinical Center (CC) 2021-08-31
NCT03638206 Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies https://ClinicalTrials.gov/show/NCT03638206 Recruiting Shenzhen BinDeBio Ltd. 2023-03-01
NCT03610360 DENdritic Cell Immunotherapy for Mesothelioma https://ClinicalTrials.gov/show/NCT03610360 Recruiting Amphera BV 2021-01-15
NCT03560973 A Double Blind, Placebo Controlled, Randomized Phase II Study Evaluating Gemcitabine With or Without Ramucirumab , for II Line Treatment MPM https://ClinicalTrials.gov/show/NCT03560973 Active, not recruiting Gruppo Oncologico Italiano di Ricerca Clinica 2019-12-22
NCT03556228 Oral TrkA Inhibitor VMD-928 for Treatment of Advanced Adult Solid Tumors or Lymphoma https://ClinicalTrials.gov/show/NCT03556228 Recruiting VM Oncology, LLC 2021-06-30
NCT03546426 Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients With PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies https://ClinicalTrials.gov/show/NCT03546426 Recruiting Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori 2021-01-31
NCT03538028 A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies https://ClinicalTrials.gov/show/NCT03538028 Recruiting Incyte Corporation 2020-09-24
NCT03517488 A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors https://ClinicalTrials.gov/show/NCT03517488 Recruiting Xencor, Inc. 2020-12-31
NCT03507452 First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin https://ClinicalTrials.gov/show/NCT03507452 Recruiting Bayer 2023-12-20
NCT03502746 Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma https://ClinicalTrials.gov/show/NCT03502746 Recruiting Hoosier Cancer Research Network 2020-06-30
NCT03420963 Ex-Vivo Expanded Allogeneic NK Cells For The Treatment Of Pediatric Solid Tumors https://ClinicalTrials.gov/show/NCT03420963 Recruiting M.D. Anderson Cancer Center 2022-12-01
NCT03412357 MesoTRAP: A Study Comparing Video-assisted Thoracoscopic Partial Pleurectomy/Decortication With Indwelling Pleural Catheter in Patients With Trapped Lung Due to Malignant Pleural Mesothelioma. https://ClinicalTrials.gov/show/NCT03412357 Recruiting Papworth Hospital NHS Foundation Trust 2019-12-01
NCT01265433 WT-1 Analog Peptide Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy https://ClinicalTrials.gov/show/NCT01265433 Completed Sellas Life Sciences Group 2017-07-25
NCT01243632 Gemcitabine in Long Infusion and Cisplatin for Malignant Pleural Mesothelioma Treatment https://ClinicalTrials.gov/show/NCT01243632 Completed Institute of Oncology Ljubljana 2010-06-30
NCT01241682 Dendritic Cell-based Immunotherapy Combined With Low-dose Cyclophosphamide in Patients With Malignant Mesothelioma https://ClinicalTrials.gov/show/NCT01241682 Completed Erasmus Medical Center 2011-10-31
NCT01212367 Intrapleural Gene Transfer for Pleural Mesothelioma https://ClinicalTrials.gov/show/NCT01212367 Completed Abramson Cancer Center of the University of Pennsylvania 2015-05-31
NCT01211275 Standard Chemotherapy With of Without Axitinib in Malignant Mesothelioma https://ClinicalTrials.gov/show/NCT01211275 Completed The Netherlands Cancer Institute 2012-11-13
NCT01204203 Pilot Study of Bisphosphonate Therapy (Zoledronic Acid) in Patients With Malignant Mesothelioma (UAB 0901) https://ClinicalTrials.gov/show/NCT01204203 Completed University of Alabama at Birmingham 2015-04-30
NCT01160458 Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With Chemotherapy https://ClinicalTrials.gov/show/NCT01160458 Completed National Institutes of Health Clinical Center (CC) 2016-08-13
NCT01134146 Radical Pleurectomy/Decortication (PD) and Intensity Modulated Radiotherapy (IMRT) https://ClinicalTrials.gov/show/NCT01134146 Completed M.D. Anderson Cancer Center 2017-07-09
NCT01126346 Quality of Life and Survivorship Care in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy (HIPEC) https://ClinicalTrials.gov/show/NCT01126346 Completed Wake Forest University Health Sciences 2011-04-30
NCT01119664 Combination Gene Transfer and Chemotherapy https://ClinicalTrials.gov/show/NCT01119664 Completed Abramson Cancer Center of the University of Pennsylvania 2013-10-14
NCT01112293 Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma https://ClinicalTrials.gov/show/NCT01112293 Completed Abramson Cancer Center of the University of Pennsylvania 2012-10-31
NCT01098266 NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed https://ClinicalTrials.gov/show/NCT01098266 Completed MolMed S.p.A. 2014-04-29
NCT01085630 Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy https://ClinicalTrials.gov/show/NCT01085630 Active, not recruiting Alliance for Clinical Trials in Oncology 2017-07-31
NCT01064648 Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma https://ClinicalTrials.gov/show/NCT01064648 Active, not recruiting National Cancer Institute (NCI) 2018-06-01
NCT01024946 Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity https://ClinicalTrials.gov/show/NCT01024946 Completed Memorial Sloan Kettering Cancer Center 2012-07-31
NCT00996567 A Study of Cetuximab Combined With Cisplatin or Carboplatin/Pemetrexed as First Line Treatment in Patients With Malignant Pleural Mesothelioma. https://ClinicalTrials.gov/show/NCT00996567 Completed University Hospital, Ghent 2015-09-30
NCT00859469 Eloxatin® Plus Gemcitabine Chemotherapy for Mesothelioma https://ClinicalTrials.gov/show/NCT00859469 Completed Columbia University 2009-03-31
NCT00821860 Video-Assisted Surgery or Talc Pleurodesis in Treating Patients With Malignant Mesothelioma https://ClinicalTrials.gov/show/NCT00821860 Completed Papworth Hospital NHS Foundation Trust 2013-02-28
NCT03608618 Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma https://ClinicalTrials.gov/show/NCT03608618 Recruiting MaxCyte, Inc. 2020-12-31
NCT01997190 Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion https://ClinicalTrials.gov/show/NCT01997190 Active, not recruiting Advantagene, Inc. 2015-12-31
NCT01776385 The ISET (Isolation by Size of Epithelial Tumor Cells) and the CellSearch Methods in Malignant Pleural Mesothelioma https://ClinicalTrials.gov/show/NCT01776385 Completed Centre Hospitalier Universitaire de Nice 2017-12-31
NCT01766739 Intra-pleural Administration of GL-ONC1, a Genetically Modified Vaccinia Virus, in Patients With Malignant Pleural Effusion: Primary, Metastases and Mesothelioma https://ClinicalTrials.gov/show/NCT01766739 Active, not recruiting Memorial Sloan Kettering Cancer Center 2021-01-31
NCT01655225 A Study of LY3023414 in Participants With Advanced Cancer https://ClinicalTrials.gov/show/NCT01655225 Active, not recruiting Eli Lilly and Company 2019-04-04
NCT01356251 Psychosocial Needs and Exploration of Online Support for Patients With Mesothelioma https://ClinicalTrials.gov/show/NCT01356251 Active, not recruiting Memorial Sloan Kettering Cancer Center 2021-11-30
NCT03531840 Olaparib in People With Malignant Mesothelioma https://ClinicalTrials.gov/show/NCT03531840 Recruiting National Institutes of Health Clinical Center (CC) 2020-06-30
NCT02903914 Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors https://ClinicalTrials.gov/show/NCT02903914 Recruiting Incyte Corporation 2020-08-28
NCT02834013 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors https://ClinicalTrials.gov/show/NCT02834013 Recruiting National Cancer Institute (NCI) 2021-08-31
NCT02399371 Pembrolizumab in Treating Patients With Malignant Mesothelioma https://ClinicalTrials.gov/show/NCT02399371 Active, not recruiting University of Chicago 2021-03-20
NCT03652077 A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies https://ClinicalTrials.gov/show/NCT03652077 Recruiting Incyte Corporation 2021-01-31
NCT00787410 An Open-label, Phase II Trial of ZD1839 (IRESSA) in Patients With Malignant Mesothelioma https://ClinicalTrials.gov/show/NCT00787410 Completed AstraZeneca 2008-04-30
NCT00770120 S0722: Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery https://ClinicalTrials.gov/show/NCT00770120 Completed Southwest Oncology Group 2014-04-30
NCT00738582 An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma https://ClinicalTrials.gov/show/NCT00738582 Completed Morphotek 2011-06-30
NCT00715611 Pleurectomy/Decortication (Neo) Adjuvant Chemotherapy and Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced Malignant Pleural Mesothelioma https://ClinicalTrials.gov/show/NCT00715611 Recruiting Memorial Sloan Kettering Cancer Center 2020-07-31
NCT00703638 Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors https://ClinicalTrials.gov/show/NCT00703638 Completed Masonic Cancer Center, University of Minnesota 2010-09-30
NCT00700336 Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II) https://ClinicalTrials.gov/show/NCT00700336 Completed CanBas Co. Ltd. 2012-07-31
NCT00652574 Dasatinib in Resectable Malignant Pleural Mesothelioma https://ClinicalTrials.gov/show/NCT00652574 Active, not recruiting M.D. Anderson Cancer Center 2019-03-31
NCT00651456 Mesothelioma Avastin Plus Pemetrexed-cisplatin Study https://ClinicalTrials.gov/show/NCT00651456 Completed Intergroupe Francophone de Cancerologie Thoracique 2015-01-31
NCT00634205 Phase II Study of Valproate and Doxorubicin in Malignant Mesothelioma https://ClinicalTrials.gov/show/NCT00634205 Completed European Lung Cancer Working Party 2009-03-31
NCT00571298 Extrapleural Pneumonectomy /Pleurectomy Decortication, IHOC Cisplatin and Gemcitabine With Amifostine and Sodium Thiosulfate Cytoprotection for Resectable Malignant Pleural Mesothelioma https://ClinicalTrials.gov/show/NCT00571298 Completed Dana-Farber Cancer Institute 2011-11-30
NCT00541073 Pemetrexed, Cisplatin, and Vitamin B12 in Treating Patients With Mesothelioma of the Chest That Cannot Be Removed by Surgery https://ClinicalTrials.gov/show/NCT00541073 Completed National Cancer Institute (NCI) 2011-05-31
NCT00535951 Pharmacokinetic, Safety, and Efficacy Effects of Oral LBH589 on Dextromethorphan in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer or Malignant Pleural Mesothelioma https://ClinicalTrials.gov/show/NCT00535951 Completed Novartis 2009-01-31
NCT00513877 Bortezomib in Treating Patients With Malignant Pleural Mesothelioma https://ClinicalTrials.gov/show/NCT00513877 Completed Cancer Trials Ireland 2009-12-31
NCT00509041 Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma https://ClinicalTrials.gov/show/NCT00509041 Completed Alliance for Clinical Trials in Oncology 2010-02-28
NCT00484276 Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Malignant Pleural Mesothelioma https://ClinicalTrials.gov/show/NCT00484276 Completed MolMed S.p.A. 2013-03-31
NCT00469196 Tomotherapy Treatment for Mesothelioma https://ClinicalTrials.gov/show/NCT00469196 Completed AHS Cancer Control Alberta 2015-05-31
NCT00459862 Pazopanib in Treating Patients With Malignant Pleural Mesothelioma https://ClinicalTrials.gov/show/NCT00459862 Completed National Cancer Institute (NCI) 2009-04-30
NCT00423254 Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer. https://ClinicalTrials.gov/show/NCT00423254 Completed Mannkind Corporation 2009-09-30
NCT00407459 Phase II Study of Bevacizumab, Pemetrexed and Carboplatin as First-Line Therapy in Malignant Pleural Mesothelioma https://ClinicalTrials.gov/show/NCT00407459 Completed Istituto Clinico Humanitas 2010-11-30
NCT00402766 Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma https://ClinicalTrials.gov/show/NCT00402766 Completed M.D. Anderson Cancer Center 2014-02-28
NCT00398138 Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma https://ClinicalTrials.gov/show/NCT00398138 Completed Memorial Sloan Kettering Cancer Center 2009-06-30
NCT00392444 Sunitinib in Treating Patients With Advanced Malignant Pleural Mesothelioma https://ClinicalTrials.gov/show/NCT00392444 Completed National Cancer Institute (NCI) 2012-01-31
NCT00386815 Safety Confirmation Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma https://ClinicalTrials.gov/show/NCT00386815 Completed Eli Lilly and Company NA
NCT00372840 Printed Education Materials in Patients Who Are Finishing Treatment for Stage I, Stage II, or Stage IIIA Breast Cancer, Colorectal Cancer, Prostate Cancer, or Chest Cancer https://ClinicalTrials.gov/show/NCT00372840 Completed Fox Chase Cancer Center 2010-11-30
NCT00365053 PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery https://ClinicalTrials.gov/show/NCT00365053 Completed National Cancer Institute (NCI) 2009-03-31
NCT00334594 Pemetrexed Disodium and Cisplatin Followed by Surgery With or Without Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma https://ClinicalTrials.gov/show/NCT00334594 Completed Swiss Group for Clinical Cancer Research 2014-03-26
NCT00325494 A Study of MORAb-009 in Subjects With Pancreatic Cancer, Mesothelioma, or Certain Types of Ovarian or Lung Cancer https://ClinicalTrials.gov/show/NCT00325494 Completed Morphotek 2008-09-30
NCT00316225 Study of Pemetrexed in Mesothelioma and Lung Cancer Patients With Fluid Around the Lungs or Abdomen https://ClinicalTrials.gov/show/NCT00316225 Completed Eli Lilly and Company 2009-03-31
NCT00309946 Cediranib Maleate in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery https://ClinicalTrials.gov/show/NCT00309946 Completed National Cancer Institute (NCI) 2010-09-30
NCT00299962 Gene Therapy for Pleural Malignancies https://ClinicalTrials.gov/show/NCT00299962 Completed University of Pennsylvania 2008-05-31
NCT00295503 Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma https://ClinicalTrials.gov/show/NCT00295503 Completed University of Texas Southwestern Medical Center 2010-06-30
NCT00280982 Dendritic Cell-based Immunotherapy in Mesothelioma https://ClinicalTrials.gov/show/NCT00280982 Completed Erasmus Medical Center 2009-09-30
NCT00272558 Study of Carboplatin and Vinorelbine in Malignant Pleural Mesothelioma https://ClinicalTrials.gov/show/NCT00272558 Completed Rigshospitalet, Denmark 2009-09-30
NCT00251550 Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma https://ClinicalTrials.gov/show/NCT00251550 Completed Eli Lilly and Company NA
NCT00243074 S0509 - AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery https://ClinicalTrials.gov/show/NCT00243074 Completed National Cancer Institute (NCI) 2010-04-30
NCT00227630 Pemetrexed Disodium and Cisplatin Followed By Surgery and Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma https://ClinicalTrials.gov/show/NCT00227630 Completed European Organisation for Research and Treatment of Cancer - EORTC 2007-08-31
NCT00190762 A Study Comparing Pemetrexed Plus Best Supportive Care Versus Best Supportive Care Alone in the Treatment of Mesothelioma https://ClinicalTrials.gov/show/NCT00190762 Completed Eli Lilly and Company NA
NCT00165555 Pleurectomy/Decortication Followed by Intrathoracic/Intraperitoneal Heated Cisplatin for Malignant Pleural Mesothelioma https://ClinicalTrials.gov/show/NCT00165555 Completed Dana-Farber Cancer Institute 2002-04-30
NCT00165516 Extrapleural Pneumonectomy With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Amifostine and Sodium Thiosulfate https://ClinicalTrials.gov/show/NCT00165516 Completed Dana-Farber Cancer Institute 2006-07-31
NCT00137826 Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma https://ClinicalTrials.gov/show/NCT00137826 Completed Dana-Farber Cancer Institute 2007-03-31
NCT00128102 Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (0683-014 AM5, EXT1) https://ClinicalTrials.gov/show/NCT00128102 Completed Merck Sharp & Dohme Corp. 2011-07-31
NCT00107432 Sorafenib Tosylate in Treating Patients With Malignant Mesothelioma. https://ClinicalTrials.gov/show/NCT00107432 Completed National Cancer Institute (NCI) 2007-06-30
NCT00101283 Pemetrexed Plus Gemcitabine or Carboplatin for Patients With Advanced Malignant Pleural Mesothelioma https://ClinicalTrials.gov/show/NCT00101283 Completed Eastern Cooperative Oncology Group 2009-09-30
NCT00003263 Cisplatin, Interferon Alfa, Surgery, and Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma https://ClinicalTrials.gov/show/NCT00003263 Completed Fox Chase Cancer Center 1999-12-31
NCT00003974 Vaccine Therapy in Treating Patients With Stage I, Stage II, or Stage IIIA Non-small Cell Lung Cancer or With Stage I or Stage II Mesothelioma https://ClinicalTrials.gov/show/NCT00003974 Completed Roswell Park Cancer Institute 1998-06-30
NCT00087698 Phase II Trial of Neo-Adjuvant Pemetrexed Plus Cisplatin Followed by Surgery and Radiation for Pleural Mesothelioma https://ClinicalTrials.gov/show/NCT00087698 Completed Eli Lilly and Company 2008-02-29
NCT00003723 S9810: Gemcitabine Plus Cisplatin in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot Be Removed by Surgery https://ClinicalTrials.gov/show/NCT00003723 Completed Southwest Oncology Group 2007-06-30
NCT00005636 Cisplatin With or Without Pemetrexed Disodium in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot be Removed by Surgery https://ClinicalTrials.gov/show/NCT00005636 Completed Memorial Sloan Kettering Cancer Center 2000-11-30
NCT00004254 Raltitrexed in Treating Patients With Malignant Mesothelioma That Cannot Be Surgically Removed https://ClinicalTrials.gov/show/NCT00004254 Completed European Organisation for Research and Treatment of Cancer - EORTC 2001-06-30
NCT00004033 Liposomal-Cisplatin Analogue (L-NDDP) in Treating Patients With Malignant Pleural Mesothelioma https://ClinicalTrials.gov/show/NCT00004033 Completed NYU Langone Health 2001-05-31
NCT00006014 SU5416 in Treating Patients With Malignant Mesothelioma https://ClinicalTrials.gov/show/NCT00006014 Completed National Cancer Institute (NCI) 2007-02-28
NCT00004183 Capecitabine in Treating Patients With Malignant Mesothelioma https://ClinicalTrials.gov/show/NCT00004183 Completed Alliance for Clinical Trials in Oncology 2003-12-31
NCT00075699 Active Symptom Control With or Without Chemotherapy in Treating Patients With Malignant Pleural Mesothelioma https://ClinicalTrials.gov/show/NCT00075699 Completed National Cancer Institute (NCI) NA
NCT00025207 Gefitinib in Treating Patients With Malignant Mesothelioma https://ClinicalTrials.gov/show/NCT00025207 Completed National Cancer Institute (NCI) 2006-02-28
NCT00066651 Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors https://ClinicalTrials.gov/show/NCT00066651 Completed National Cancer Institute (NCI) NA
NCT00066404 Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions https://ClinicalTrials.gov/show/NCT00066404 Completed Abramson Cancer Center of the University of Pennsylvania 2006-01-31
NCT00062283 Alanosine in Treating Patients With Cancer https://ClinicalTrials.gov/show/NCT00062283 Completed National Cancer Institute (NCI) 2005-12-31
NCT00061477 Pemetrexed Plus Gemcitabine as Front-Line Chemotherapy for Patients With Malignant Pleural or Peritoneal Mesothelioma https://ClinicalTrials.gov/show/NCT00061477 Completed Eli Lilly and Company NA
NCT00797719 Short Neoadjuvant Hemithoracic IMRT for MPM https://ClinicalTrials.gov/show/NCT00797719 Recruiting University Health Network, Toronto 2020-07-31
NCT00054002 Surgery and Photodynamic Therapy in Treating Patients With Malignant Mesothelioma https://ClinicalTrials.gov/show/NCT00054002 Completed Roswell Park Cancer Institute 2006-06-30
NCT00053885 PTK787/ZK 222584 in Treating Patients With Unresectable Malignant Mesothelioma https://ClinicalTrials.gov/show/NCT00053885 Completed Alliance for Clinical Trials in Oncology 2005-07-31
NCT00039182 Erlotinib in Treating Patients With Malignant Mesothelioma of the Lung https://ClinicalTrials.gov/show/NCT00039182 Completed National Cancer Institute (NCI) 2007-06-30
NCT00030745 Combination Chemotherapy Before Surgery in Treating Patients With Mesothelioma of the Lung https://ClinicalTrials.gov/show/NCT00030745 Completed Swiss Group for Clinical Cancer Research 2003-05-31
NCT00030498 Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction https://ClinicalTrials.gov/show/NCT00030498 Completed National Cancer Institute (NCI) 2007-07-31
NCT00027703 Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma https://ClinicalTrials.gov/show/NCT00027703 Completed National Cancer Institute (NCI) 2006-05-31
NCT00024076 Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer https://ClinicalTrials.gov/show/NCT00024076 Completed Jonsson Comprehensive Cancer Center 2006-12-31
NCT00020124 Inhaled Doxorubicin in Treating Patients With Advanced Solid Tumors Affecting the Lungs https://ClinicalTrials.gov/show/NCT00020124 Completed National Institutes of Health Clinical Center (CC) NA
NCT00019825 Decitabine in Treating Patients With Unresectable Lung or Esophageal Cancer or Malignant Mesothelioma of the Pleura https://ClinicalTrials.gov/show/NCT00019825 Completed National Cancer Institute (NCI) NA
NCT00017186 Gemcitabine and Epirubicin in Treating Patients With Malignant Mesothelioma https://ClinicalTrials.gov/show/NCT00017186 Completed Alliance for Clinical Trials in Oncology 2004-08-31
NCT00006981 Immunotoxin Therapy in Treating Patients With Advanced Cancer https://ClinicalTrials.gov/show/NCT00006981 Completed National Cancer Institute (NCI) NA
NCT00006231 Radiation Therapy in Preventing Metastatic Cancer in Patients Who Have Diagnostic Procedures to Identify Malignant Mesothelioma https://ClinicalTrials.gov/show/NCT00006231 Completed National Cancer Institute (NCI) NA
NCT00004920 Cisplatin With or Without Raltitrexed in Treating Patients With Malignant Mesothelioma of the Pleura https://ClinicalTrials.gov/show/NCT00004920 Completed European Organisation for Research and Treatment of Cancer - EORTC 2003-01-31
NCT00002608 Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors https://ClinicalTrials.gov/show/NCT00002608 Completed National Cancer Institute (NCI) NA
NCT00002475 Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer https://ClinicalTrials.gov/show/NCT00002475 Completed National Cancer Institute (NCI) 2007-12-31
NCT00037817 Phase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion With or Without Concurrent Celecoxib in Subjects With Pulmonary and Pleural Malignancies https://ClinicalTrials.gov/show/NCT00037817 Completed National Institutes of Health Clinical Center (CC) 2008-10-08
NCT00458913 Bortezomib and Cisplatin as First-Line Therapy in Treating Patients With Malignant Mesothelioma https://ClinicalTrials.gov/show/NCT00458913 Completed European Organisation for Research and Treatment of Cancer - EORTC 2010-04-30
NCT00004547 Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and Chemotherapy https://ClinicalTrials.gov/show/NCT00004547 Completed National Institutes of Health Clinical Center (CC) 2009-08-31

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT03034850 Thrombin Generation and Platelet Activation in CRS/HIPEC https://ClinicalTrials.gov/show/NCT03034850 Completed Ziekenhuis Oost-Limburg 2016-07-31
NCT02958683 Chest Wall Motion Analysis in Disease https://ClinicalTrials.gov/show/NCT02958683 Completed Heart of England NHS Trust 2015-07-31
NCT02948413 Influence of Psychosocial Distress and Lifetime Trauma Exposure on Traumatic Stress Among Oncology Patients on Clinical Trials https://ClinicalTrials.gov/show/NCT02948413 Completed National Institutes of Health Clinical Center (CC) 2020-04-27
NCT02834234 Genomic Analysis of Peritoneal Mesothelioma by CGH Arrays https://ClinicalTrials.gov/show/NCT02834234 Completed Hospices Civils de Lyon 2016-01-31
NCT02648763 Staging Procedures to Diagnose Malignant Pleural Mesothelioma https://ClinicalTrials.gov/show/NCT02648763 Recruiting Mayo Clinic 2020-12-31
NCT02613312 Chemotherapy Followed by Surgery and Neoadjuvant Hemothoracic Intensity Modified Radiation Therapy (IMRT) for Patients With Malignant Pleural Mesothelioma https://ClinicalTrials.gov/show/NCT02613312 Recruiting Mayo Clinic 2020-12-31
NCT02613299 Surgery for Mesothelioma After Radiation Therapy “SMART” for Resectable Malignant Pleural Mesothelioma https://ClinicalTrials.gov/show/NCT02613299 Recruiting Mayo Clinic 2020-12-31
NCT02603315 Vascularity Impact on the Treatment Outcome in Malignant Pleural Mesothelioma(VITMPM) https://ClinicalTrials.gov/show/NCT02603315 Completed Ain Shams University 2016-05-31
NCT02269878 Effect of FAS and FAS Ligand Polymorphisms on Patients With Platinum-Based -Treated Malignant Pleural Mesothelioma https://ClinicalTrials.gov/show/NCT02269878 Completed Ain Shams University 2016-06-30
NCT01773655 Clinical and Histopathologic Characteristics of BAP1 Mutations https://ClinicalTrials.gov/show/NCT01773655 Completed Memorial Sloan Kettering Cancer Center 2020-06-30
NCT00242723 Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining https://ClinicalTrials.gov/show/NCT00242723 Recruiting National Institutes of Health Clinical Center (CC) NA
NCT01950572 Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma https://ClinicalTrials.gov/show/NCT01950572 Recruiting National Institutes of Health Clinical Center (CC) 2033-07-25
NCT01851395 Rapid Autopsy and Procurement of Cancer Tissue https://ClinicalTrials.gov/show/NCT01851395 Recruiting National Institutes of Health Clinical Center (CC) 2024-03-31
NCT01812148 Survival of Peritoneal Mesothelioma After Cytoreductive Surgery and Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) https://ClinicalTrials.gov/show/NCT01812148 Completed Maisonneuve-Rosemont Hospital 2013-03-31
NCT01617382 Register With Patients in Which Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) Was Performed https://ClinicalTrials.gov/show/NCT01617382 Recruiting Universitaire Ziekenhuizen Leuven 2025-01-31
NCT01590472 Do Your Genes Put You at a Higher Risk of Developing Mesothelioma https://ClinicalTrials.gov/show/NCT01590472 Completed Wake Forest University Health Sciences 2014-12-31
NCT01416714 Tissue Procurement for Gastric Cancer, Gastrointestinal Stromal Tumors (GIST), Esophageal Cancer, Pancreas Cancer, Hepatocellular Cancer, Biliary Cancer, Neuroendocrine, Peritoneal Mesothelioma, Anal Cancer and Colorectal Cancer in Patients Undergoing Surgery or Biopsy https://ClinicalTrials.gov/show/NCT01416714 Recruiting University of Chicago 2025-01-31
NCT01385722 Molecular Analysis of Thoracic Malignancies https://ClinicalTrials.gov/show/NCT01385722 Enrolling by invitation Stanford University 2031-06-30
NCT04214015 A Pilot Study to Explore the Role of Gut Flora in Metastatic Mesothelioma https://ClinicalTrials.gov/show/NCT04214015 Recruiting ProgenaBiome 2023-03-31
NCT03830229 Long Term Follow-up of Mesothelioma Patients and Their Family Members With Germline Mutations in BAP1 and Other Genes https://ClinicalTrials.gov/show/NCT03830229 Recruiting National Institutes of Health Clinical Center (CC) 2026-07-06
NCT03537833 Association Between Proton Pump Inhibitors and Hematologic Toxicity of Pemetrexed https://ClinicalTrials.gov/show/NCT03537833 Recruiting CHU de Reims 2020-11-02
NCT01135849 B-Receptor Signaling in Cardiomyopathy https://ClinicalTrials.gov/show/NCT01135849 Completed Stanford University 2010-10-31
NCT00897442 Collecting Tumor Samples From Patients With Gynecological Tumors https://ClinicalTrials.gov/show/NCT00897442 Completed Gynecologic Oncology Group 2016-01-31
NCT00897247 Biomarkers to Detect Mesothelioma Early in Patients Exposed to Asbestos or Vermiculite https://ClinicalTrials.gov/show/NCT00897247 Completed Barbara Ann Karmanos Cancer Institute 2013-03-31
NCT00867711 Molecular Predictors of Pemetrexed and Carboplatin Response in Malignant Pleural Mesothelioma (MPM) Patients https://ClinicalTrials.gov/show/NCT00867711 Completed Istituto Clinico Humanitas 2011-12-31
NCT02467426 Isolated Thoracic Perfusion (ITP-F) for MPM https://ClinicalTrials.gov/show/NCT02467426 Completed Medias Klinikum for Surgical Oncology 2015-01-31
NCT02029105 Serum Biomarkers in Diagnosis of Mesothelioma https://ClinicalTrials.gov/show/NCT02029105 Completed Eskisehir Osmangazi University 2010-12-31
NCT00188890 Early Diagnosis of Lung Cancer and Mesothelioma in Prior Asbestos Workers https://ClinicalTrials.gov/show/NCT00188890 Completed University Health Network, Toronto 2019-07-03

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT03210298 International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) https://ClinicalTrials.gov/show/NCT03210298 Recruiting University of Magdeburg 2022-09-30
NCT02073500 Peritoneal Surface Malignancies - Characterization, Models and Treatment Strategies https://ClinicalTrials.gov/show/NCT02073500 Recruiting Oslo University Hospital 2017-01-31
NCT02012699 Integrated Cancer Repository for Cancer Research https://ClinicalTrials.gov/show/NCT02012699 Recruiting University of Nebraska 2099-12-31